arrow
T

Thomas Karn

university of frankfurt
H指数:46
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial

阿特珠单抗治疗早期三阴性乳腺癌: 随机3期NSABP B-59/gepandouze试验

2026-09-010
OA
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort

HER2低表达和超低表达乳腺癌的临床与分子学评估:PENELOPE-B临床试验队列研究

2026-04-210
PRE
Diagnostic accuracy of phosphatase and tensin homolog loss in differentiating between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia and non-atypical endometrial hyperplasia: A systematic review and meta-analysis

磷酸酶和张力蛋白同源物丢失在区分非典型子宫内膜增生/子宫内膜样上皮内瘤变与非非典型子宫内膜增生中的诊断准确性:一项系统评价和荟萃分析

2026-02-260
OAAI
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

远处无病生存期作为早期乳腺癌新辅助治疗随机试验中总生存期的替代终点:GBG和AGO-B研究组试验的合并分析

2025-11-240
PRE
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification

妊娠对乳腺癌免疫学的影响:免疫生物标志物和TIL量化

2025-05-140
OA
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

靶向PI3K抑制剂耐药性:乳腺癌中的代谢药物应用

2025-03-210
OA
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
2024-11-010
OAAI
Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial

RAD51与HER2阴性乳腺癌(BC)患者中同源重组缺陷(HRD)疗效结局的关联:GeparOla试验的事后分析

2024-09-010
PRE
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
2024-06-053
PRE
CDH1 mutations predict resistance to neoadjuvant taxane therapy
2024-05-020
PRE
Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial
2024-05-020
PRE
Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients
2024-04-250
OAAI
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
2023-07-115
OA
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
2023-04-044
OAAI
Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy
2023-03-010
PRE